title: Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein.
abstract: Human femoral, internal mammary, and gastroepiploic arteries and saphenous veins are used as bypass grafts for coronary surgery or for reconstruction in arterial occlusive disease. We have characterized the contractile responses of these vessels to various agents that are liberated during cardiac or vascular surgery. In organ baths, U46619 (a stable thromboxane A2 mimetic), norepinephrine, endothelin-1, angiotensin II, and KCl caused concentration-dependent contractions in all vessels tested. Leukotriene C4 did not induce any contraction in the arteries, whereas a contraction was obtained in the saphenous vein rings. U46619 induced the most powerful contraction in all vessels tested. The pD2 values for each agent did not differ among the different vessels. When responses were expressed as a percentage of KCl-induced contraction, the contraction of endothelin-1 (151+/-5%) and leukotriene C4 (43+/-5%) was more significant on saphenous veins than on arteries. In conclusion, thromboxane A2 appears to be the most potent endogenous constricting agent on different human vascular beds. Our second finding is that saphenous veins are more sensitive to contract to leukotriene C4 and endothelin-1 than arteries. These properties may influence early and (or) long-term vein graft patency.
authors.affiliation: Pharmacology Laboratory, PCEBM, Faculté de Médecine de Grenoble, France. Jean-Luc.Cracowski@ujf-grenoble.fr
authors.forename: J L
authors.initials: JL
authors.lastname: Cracowski
authors.forename: F
authors.initials: F
authors.lastname: Stanke-Labesque
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: M
authors.initials: M
authors.lastname: Hunt
authors.forename: O
authors.initials: O
authors.lastname: Chavanon
authors.forename: P
authors.initials: P
authors.lastname: Devillier
authors.forename: G
authors.initials: G
authors.lastname: Bessard
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000494:pharmacology; D005263:Femoral Artery / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D017997:Leukotriene C4 / Q000494:pharmacology; D008323:Mammary Arteries / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D012501:Saphenous Vein / Q000187:drug effects / Q000502:physiology*; D012680:Sensitivity and Specificity; D013270:Stomach / Q000098:blood supply*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D019332:Endothelin-1; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D017997:Leukotriene C4; D011189:Potassium Chloride; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D009638:Norepinephrine